SEOUL, South Korea|September 06, 2025 – With a bold focus on transformative technologies like AI-powered drug discovery, personalized medicine breakthroughs, and sustainable manufacturing practices, BIOPLUS-INTERPHEX KOREA (BIX) 2025 is poised to be the ultimate destination for biopharma leaders and innovators. Scheduled for October 15-17, 2025, at COEX Seoul, this year’s edition aims to serve as a catalyst for real-world progress across the global biopharma value chain.
Innovation Blooms at BIX 2025
Under the theme “Innovation Blooms No Matter What,” the BIX 2025 conference is designed as a springboard for addressing the industry’s most pressing challenges and opportunities. This year’s program features an impressive 36 sessions, including high-level keynotes,
16 Insight Sessions led by global pioneers, and 20 Technical Sessions offering field-specific expertise in R&D, regulatory strategies, and market commercialization. Ahead of the full program announcement, here’s a preview of two standout keynote sessions
and eight pivotal sessions that are set to shape the future of the biopharma industry:
Keynote Speakers and Breakthrough Sessions at BIX 2025
BIX 2025 is proud to present an exclusive preview of two remarkable keynote sessions and eight pivotal discussions that promise to shape the biopharmaceutical landscape. These sessions feature industry-leading experts and focus on new innovations and strategies driving the future of biopharma.
Dr. Robert J. Hariri, Chairman & CEO, Celularity, Inc.
A trailblazer in biomedical science and cell-based therapeutics, Dr. Hariri brings decades of expertise to the stage. Renowned for being the first to isolate pluripotent stem cells from the human placenta, his groundbreaking advancements in immuno-oncology, regenerative medicine, and cell therapy continue to redefine the field.
Keynote Address: October 15 (Day 1), 10:15–10:45 AM, Room 401
Dr. David Berry, General Partner, Flagship Pioneering
A visionary biotech entrepreneur and thought leader, Dr. Berry has founded several game-changing startups, including Seres Therapeutics and Valo Health. His pioneering work in AI, the microbiome, and synthetic biology is transforming the way medicines and biotechnologies
are conceptualized and delivered.
Keynote Address: October 16 (Day 2), 9:00–10:00 AM, Studio 159
Eight Breakthrough Sessions to Watch
AI in Drug Development: Real-World Applications and Limitations
Examine real-world applications of artificial intelligence in identifying drug targets, optimizing molecular design, and advancing clinical decision-making. This session, featuring case studies from global pharmaceutical leaders, showcases AI’s game-changing potential while addressing its current limitations.
Anti-Aging as the Next Biotech Frontier
Delve into the revolutionary advancements driving the anti-aging sector, including scientific breakthroughs, regulatory challenges, and commercial opportunities. This session outlines pathways to leverage this booming market.
Scaling Digital Health Globally
Learn from Korean innovators on the forefront of digital health. From securing FDA approvals to forging global healthcare collaborations, this session highlights technologies that are reshaping patient care on an international scale.
New-Co Models: Risk Diversification or Scalable Innovation?
Industry leaders debate the strategic value of New-Co structures. Are these spin-offs the next leap in scalable innovation or merely tools for managing risk? Gain insights into what makes or breaks success in this evolving business approach.
Must Know About Navigating New Changes at US FDA: FDA’s Enhanced Foreign Inspections, Domestic Manufacturing Incentives, Artificial Intelligence Integration and More
With evolving FDA regulations, this session offers crucial guidance for Korean life sciences firms. Explore policy shifts around foreign manufacturing inspections, U.S.-based production incentives, and AI integration in regulatory processes, all explained by top-notch FDA experts.
RLT (RadioLigand Therapy) Radiopharma Revolution: Unmet Needs, Innovation, and Global Access
Explore how radioligand therapy is revolutionizing cancer treatment. This world-class session covers innovation, global access, and unmet needs in precision medicine.
China Biotech’s ‘Deepseek’ Moment Is Coming. Are You Ready?
Analyze China’s meteoric rise in biotechnology, fueled by government initiatives and bold strategies for global expansion. Gain practical strategies for capitalizing on collaboration opportunities with this major market player.
Licensing-Out Strategies for K-Bio
Designed for Korean biopharma companies aiming to succeed globally, this session explores preclinical strategies, critical data requirements, and effective collaboration models, offering clear and actionable steps for global technology transfer.
More Than Ideas, It’s Where Connections Happen
At BIX 2025, innovation meets action. Beyond the sessions, the exhibition will showcase 550 booths from over 300 companies, featuring top-notch technologies and products already in use across the industry. With a focus on actionable insights and interactive opportunities, attendees can connect with global thought leaders, policymakers, and market drivers, while exploring real-world solutions and engaging directly with the innovators shaping the future of the biopharma sector.
Secure Your Spot at BIX 2025
This year, BIX offers a range of passes designed to meet the unique needs of biotech professionals at every level:
All-Inclusive Pass: Full access to all conference sessions, exhibitions, and VIP networking programs. Exhibition Executive Pass: Curated for senior leaders focused on business development and licensing.
EE (Exhibition Executive) Pass: Focused on business matchmaking and high-level networking with exhibitors. Ideal for: Senior managers in business development, licensing, and distribution.
Standard Pass: Ideal for specialists in R&D, regulatory affairs, and global marketing.
Entry Pass: Perfect for attendees from academia, research institutions, and public-sector organizations.